# Rallybio (stock symbol: RLYB) Logo in transparent PNG and SVG formats

## Rallybio Logo large

### Rallybio Logo large Download PNG (38.84 KB)

![Rallybio Logo large Download PNG (38.84 KB)](/img/orig/RLYB_BIG-83f29b44.png)

### Rallybio Logo large Download SVG (2.04 KB)

![Rallybio Logo large Download SVG (2.04 KB)](/img/orig/RLYB_BIG-ad49ac51.svg)

## Rallybio Logo icon format

### Rallybio Logo icon format Download PNG (38.36 KB)

![Rallybio Logo icon format Download PNG (38.36 KB)](/img/orig/RLYB-4a2688d8.png)

### Rallybio Logo icon format Download SVG (950 Bytes)

![Rallybio Logo icon format Download SVG (950 Bytes)](/img/orig/RLYB-9a38b9a7.svg)

## Rallybio Logo large for dark backgrounds

### Rallybio Logo large for dark backgrounds Download PNG (37.43 KB)

![Rallybio Logo large for dark backgrounds Download PNG (37.43 KB)](/img/orig/RLYB_BIG.D-f663ae0d.png)

### Rallybio Logo large for dark backgrounds Download SVG (2.04 KB)

![Rallybio Logo large for dark backgrounds Download SVG (2.04 KB)](/img/orig/RLYB_BIG.D-67c1c57a.svg)

## Rallybio Logo icon format for dark backgrounds

### Rallybio Logo icon format for dark backgrounds Download PNG (36.93 KB)

![Rallybio Logo icon format for dark backgrounds Download PNG (36.93 KB)](/img/orig/RLYB.D-a22db615.png)

### Rallybio Logo icon format for dark backgrounds Download SVG (950 Bytes)

![Rallybio Logo icon format for dark backgrounds Download SVG (950 Bytes)](/img/orig/RLYB.D-d7f03f69.svg)

## About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

1. Website domain: rallybio.com
2. Employees: 44
3. Marketcap: $0.20 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ§¬ Biotech
